Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)							
Title of Invention	SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION						
As the below	named inventor(s), I/we declare that:						
This declarat	ion is directed to:						
	The attached application, (and Preliminary Amendment, if applicable), or (FCT/1804103338)						
	Application No. 10/583,782, filed on 06/19/2006						
: :	as amended on (if applicable);						
I/we believe th sought;	I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;						
I/we have revie amendment sp	ewed and understand the contents of the above-identified application, including the claims, as amended by any pecifically referred to above;						
material to pat became availa	dge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be entability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which ble between the filing date of the prior application and the national or PCT International filing date of the part application.						
	WARNING						
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.							
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.							
Full Name of Inventor(s)							
Inventor 1	Mark L. Boys						
Signature	Mark L Boyo Citizen of US						
Inventor 2	Michael Clare						
Signature	Citizen of United Kingdom						
X Additiona	Inventors are being named on next page						

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/01A (10-05)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)								
Title of S	SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION							
As the below no	amed inventor(s), I/we declare that:							
This declaration	n is directed to:							
	The attached application, (and Preliminary Amendment, if applicable), or							
	(PCT/IBOHID 3238)  Application No. 10/583,782, filed on 06/19/2006							
	as amended on (if applicable);							
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;								
I/we have review amendment spec	ed and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;							
material to paten	··							
	WARNING							
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.								
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.								
Full Name of Inventor(s)								
Inventor 1	Mark L. Boys							
Signature	Citizen of Britian							
Inventor 2	Michael Clare							
Signature	Citizen of United Kingdom							
X Additional in	ventors are being named on next page							

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/01A (10-05)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN							
APPLICATION DATA SHEET (37 CFR 1.76)							
Title of S	SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION						
As the below named inventor(s), I/we declare that:							
This declaration is directed to:							
	The attached application, (and Preliminary Amendment, if applicable), or  (PCT/IB04/63238)  Application No. 10/583,782, filed on 06/19/2006						
	as amended on (if applicable);						
I/we believe that sought;	I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is						
I/we have review amendment spec	red and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;						
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.							
	WARNING						
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.  All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable							
by fine or imprison thereon.	onment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing						
Full Name of I	nventor(s)						
Inventor 3	Mark J. Mitton-Fry						
Signature	Mare Mitter S Citizen of us						
☐ Additional in	ventors are being named on						

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/81(06-03)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM			Application Number		10/583,782/ PCT/1B04/03238		
			ate		06/19/2006		
			med Inven	tor	Mark L. Boys		
				· · · ·	SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION		
					ON THE INCAMBERT OF INTERMS	IIATION .	
			er Name	,,			
		Attorne	y Docket N	lumber	PC28082A		
I hereby appoint:							
Practitioners at Custor	mer Number	285	23	]			
OR							
Practitioners named be	elow:					ļ	
	Name			Registrati	on Number		
						1	
	<del></del>					1	
	-						
as my/our attorney(s) or age	nt(s) to prosecute the applications S Patent and Trademark Office	n identified	above, and	d to transact	all		
-	the correspondence address for			application t	n·		
The above-mentioned			, identified	арриоапол	<b>.</b>		
OR	Customer Number.						
The address associated with Customer Number  OR							
Firm or Individual Name							
Address							
Address				- <u>-</u>			
City		8	State		Zip		
Country							
Telephone		Fa	ax				
I am the:						V	
Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name	Name Mark L. Boys						
Signature MonR I		Box 10			14 NOV- 2006		
Date 10th Nov-2006							
NOTE: Signatures of all the inve forms if more than one signature	entors or assignees of record of e is required, see below*.	the entire i	nterest or t	heir represe	ntative(s) are required. Submit mult	iple	
★ Total of 3 forms are submitted.  ★ Total of	ed.						

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/81(06-03)

10/583,782 PCT/1A AU/AZ DAR

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM			Date		06/19/2006		
			lamed Inv	entor	Mark L. Boys		
					SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION		
			it				
INDICATIO	IN FURIVI	Exami	ner Name				
****		Attorn	ey Docket	Number	PC28082A		
I hereby appoint:							
Practitioners at Custom	ner Number	28	523	7			
OR							
Practitioners named be	elow:						
	Name		<del></del>	Registrati	ion Number		
,							
as my/our attorney(s) or ager business in the United States	it(s) to prosecute the app Patent and Trademark (	lication identifie Office connecter	d above, a therewith	ind to transact	all		
Please recognize or change					0.		
		coo for the above	rc-identille	a application t	<b>0</b> .		
The above-mentioned OR	Customer Number.						
OR .							
The address associate	d with Customer Number	•					
OR					•		
Firm or Individual Name							
Address							
Address							
City			State		Zip		
Country			515.15		2.10		
Telephone			Fax				
		L					
I am the:  Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71.							
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name	Name Michael Clare						
Signature	16	Unill	U	1/4			
Date	9th Nova	mber	200	76			
NOTE: Signatures of all the inveforms if more than one signature	ntors or assignees of receis required, see below*.	ord of the entire	interest or	r their represer	ntative(s) are required. Submit multiple		
★Total of 3 forms are submitted.	ed.						

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applicat	ion Numbe	)r	10/583,782 PCT/160	4103238	
	Filing Date			06/19/2006			
POWER OF	ATTORNEY	First Nar	med Invent	ior	Mark L. Boys		
an		Title		•	SUBSTITUTED PYRAZIN	IONE COMPOUNDS	
CORRESPONDE		Art Unit					
INDICATION	IN FURIVI	Examine	r Name				
		Attorney	Docket Nu	umber	PC28082A		
I hereby appoint:				_			
Practitioners at Custon	ner Number	2852	28523				
OR	<u> </u>			I	•		
Practitioners named be	elow:						
	Name		Registration Number				
as my/our attorney(s) or ager business in the United States	nt(s) to prosecute the application s Patent and Trademark Office c	in identified : connected t	above, and herewith.	to transact	ı <b>ali</b>		
	the correspondence address for			application t	ro:		
The above-mentioned				PP	<b>o</b> .		
OR ·	Oustonio, Hambo.,						
	ed with Customer Number			7			
OR .				_			
Firm or							
Individual Name	I		•	•			
Address				<del></del>			
Address				-			
City		s	tate		Zip		
Country					<u> 1</u>		
Telephone		Fa	х				
I am the:							
Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name	Mark J. Mitton-Fry						
Signature	Marz J. My	dis	<del>\</del>				
Date	15 14 14 15						
NOTE: Signatures of all the inveforms if more than one signature	entors or assignees of record of t	the entire in	terest or th	eir represer	ntative(s) are required. S	ubmit multiple	
	ed.						

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.